Results of a Safety Initiative for Patients on Concomitant Amiodarone and Simvastatin Therapy in a Veterans Affairs Medical Center

BACKGROUND: The FDA revised the labels of amiodarone and simvastatin in 2002 to warn of increased risk of rhabdomyolysis, the most severe form of myopathy, when the 2 drugs are taken concomitantly in doses greater than 20 milligrams (mg) per day of simvastatin. The FDA reissued the warning in 2008 a...

Descripción completa

Detalles Bibliográficos
Autores principales: Karimi, Sahar, Hough, Augustus, Beckey, Cherylyn, Parra, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437393/
https://www.ncbi.nlm.nih.gov/pubmed/20726676
http://dx.doi.org/10.18553/jmcp.2010.16.7.472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437393/
https://www.ncbi.nlm.nih.gov/pubmed/20726676
http://dx.doi.org/10.18553/jmcp.2010.16.7.472

Ejemplares similares